These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. A case of recurrent ovarian cancer successfully treated with adoptive immunotherapy and lentinan. Fujimoto K; Tomonaga M; Goto S Anticancer Res; 2006; 26(6A):4015-8. PubMed ID: 17195451 [TBL] [Abstract][Full Text] [Related]
8. Cell surface density of p185(c-erbB-2) determines susceptibility to anti-p185(c-erbB-2)-ricin A chain (RTA) immunotoxin therapy alone and in combination with anti-p170(EGFR)-RTA in ovarian cancer cells. Dean GS; Pusztai L; Xu FJ; O'Briant K; DeSombre K; Conaway M; Boyer CM; Mendelsohn J; Bast RC Clin Cancer Res; 1998 Oct; 4(10):2545-50. PubMed ID: 9796989 [TBL] [Abstract][Full Text] [Related]
9. Biologic therapy in the management of refractory ovarian cancer. Bookman MA Gynecol Oncol; 1993 Oct; 51(1):113-26. PubMed ID: 8244165 [TBL] [Abstract][Full Text] [Related]
10. IL-2 enhances standard IFNgamma/LPS activation of macrophage cytotoxicity to human ovarian carcinoma in vitro: a potential for adoptive cellular immunotherapy. Han X; Wilbanks GD; Devaja O; Ruperelia V; Raju KS Gynecol Oncol; 1999 Nov; 75(2):198-210. PubMed ID: 10525372 [TBL] [Abstract][Full Text] [Related]
11. Biologic therapy and immunotherapy for ovarian cancer. Bookman MA Curr Opin Oncol; 1991 Oct; 3(5):901-7. PubMed ID: 1751581 [TBL] [Abstract][Full Text] [Related]
14. Adoptive immunotherapy using human peripheral blood lymphocytes transferred with RNA encoding Her-2/neu-specific chimeric immune receptor in ovarian cancer xenograft model. Yoon SH; Lee JM; Cho HI; Kim EK; Kim HS; Park MY; Kim TG Cancer Gene Ther; 2009 Jun; 16(6):489-97. PubMed ID: 19096447 [TBL] [Abstract][Full Text] [Related]
15. Targeting of interleukin 2 to human ovarian carcinoma by fusion with a single-chain Fv of antifolate receptor antibody. Melani C; Figini M; Nicosia D; Luison E; Ramakrishna V; Casorati G; Parmiani G; Eshhar Z; Canevari S; Colombo MP Cancer Res; 1998 Sep; 58(18):4146-54. PubMed ID: 9751627 [TBL] [Abstract][Full Text] [Related]
17. Immunomodulation in patients with epithelial ovarian cancer after adoptive transfer of tumor-infiltrating lymphocytes. Ikarashi H; Fujita K; Takakuwa K; Kodama S; Tokunaga A; Takahashi T; Tanaka K Cancer Res; 1994 Jan; 54(1):190-6. PubMed ID: 8261438 [TBL] [Abstract][Full Text] [Related]
18. Sperm protein 17 is a suitable target for adoptive T-cell-based immunotherapy in human ovarian cancer. Chiriva-Internati M; Weidanz JA; Yu Y; Frezza EE; Jenkins MR; Kennedy RC; Cobos E; Kast WM J Immunother; 2008 Oct; 31(8):693-703. PubMed ID: 18779750 [TBL] [Abstract][Full Text] [Related]
19. Enhanced killing of primary ovarian cancer by retargeting autologous cytokine-induced killer cells with bispecific antibodies: a preclinical study. Chan JK; Hamilton CA; Cheung MK; Karimi M; Baker J; Gall JM; Schulz S; Thorne SH; Teng NN; Contag CH; Lum LG; Negrin RS Clin Cancer Res; 2006 Mar; 12(6):1859-67. PubMed ID: 16551871 [TBL] [Abstract][Full Text] [Related]
20. Harnessing the immune system for ovarian cancer therapy. Odunsi K; Sabbatini P Am J Reprod Immunol; 2008 Jan; 59(1):62-74. PubMed ID: 18154597 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]